Andres Cubillos-Ruiz
Seminars
Tuesday 24th June 2025
Panel Discussion: From Consumer Success to Clinical Impact: How Direct-to-Consumer Microbiome Products Are Shaping Therapeutic Breakthroughs
4:30 pm
- Evaluating clinical trial strategies for direct-to-consumer microbiome products: costs, regulatory pathways, and scientific credibility
- Analyzing the economic viability of trial-based models in the DTC space: profitability, investor interest, and commercialization speed
- Navigating marketing and regulatory constraints for microbiome therapeutics in a consumer-driven landscape
Wednesday 25th June 2025
Engineering Probiotics to Safeguard the Gut Microbiome During Antibiotic Therapy
12:00 pm
- Impact of Antibiotics on the Gut Microbiome: Exploring how common antibiotic treatments
- Introduction to FLR-101, an engineered yeast strain designed to produce enzymes that locally degrade specific antibiotics in the gut, thereby managing impacts to the microbiome without compromising the efficacy of the treatment
- Regulatory Strategy and Medical Food Classification: Discussing Florey's unique approach to navigating regulatory pathways by developing FLR-101 as a medical food, aiming for efficient market entry and broad accessibility
- Future Directions in Engineered Probiotics: Outlining plans for expanding the application of Florey's synthetic biology platform to develop additional probiotics targeting various health conditions influenced by the gut microbiome
